Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 7

Genetic, host, and environmental interactions in a 19 year old with severe chronic obstructive lung disease; observations regarding the pathophysiology of airflow obstruction

Authors Grosu HB, Killam J, Khusainova E, Lozada J,Needelman A, Eden E

Published Date June 2012 Volume 2012:7 Pages 383—388

DOI http://dx.doi.org/10.2147/COPD.S30325

Received 29 January 2012, Accepted 7 March 2012, Published 22 June 2012

Horiana B Grosu,1 Jonathan Killam,2 Elvina Khusainova,3 James Lozada,1 Andrew Needelman,4 Edward Eden1

1Division of Pulmonary Critical Care and Sleep Medicine, 2Department of Radiology, 3Department of Medicine, St Luke's Roosevelt Hospital Center, New York, 4Mid Hudson Medical Group, Poughkeepsie, New York, USA

Abstract: A case of a 19-year-old with severe chronic obstructive pulmonary disease is presented. This case illustrates genetic (severe alpha-1 antitrypsin deficiency) and host factors (such as developmental diaphragmatic hernia and the innate response to injury), and environmental (high oxidative stress and lung injury) interactions that lead to severe chronic obstructive lung disease. The development of chronic lung disease was caused by lung injury under high oxidative and inflammatory conditions in the setting of a diaphragmatic hernia. In the absence of normal alpha-1 antitrypsin levels, a pro-elastolytic environment in the early period of lung growth enhanced the development of severe hyperinflation and precocious airflow obstruction.

Keywords: Swyer James Macleod syndrome, alpha-1 antitrypsin deficiency, bronchopulmonary dysplasia, chronic obstructive pulmonary disease

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations

Pomares X, Montón C, Espasa M, Casabon J, Monsó E, Gallego M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:449-456

Published Date: 6 September 2011

Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD

Hareendran A, Leidy NK, Monz BU, Winnette R, Becker K, Mahler DA

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:345-355

Published Date: 28 May 2012

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol

Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:375-382

Published Date: 20 June 2012